Pensacola, Fla.-based Regenative Labs (Regenative), a manufacturer of human cells, tissues, or cellular or tissue-based products, announces advancements in breast reduction post-surgical complication care.
Board-certified regenerative medicine specialist Allen Meglin, MD, of Advanced Regenerative Therapy in Savannah, Ga., has presented a novel case study of Wharton’s jelly used on a patient with a complicated cosmetic post-surgical wound. The homologous use application uncovered by Meglin results from his commitment to outcomes-based medicine, and to delivering strong patient care.
“What I’ve seen here represents an advancement that may provide hope for patients suffering emotional distress and disfigurement from post-surgical complications of breast reduction,” says Meglin. “With Wharton’s Jelly, we were able to close a wound that would normally take three months, in three weeks.”
According to the American Board of Plastic Surgeons, more than 90,000 breast reductions are performed each year. Moroever, reduction mammaplasty has a post-surgical complication rate of up to 54%. Complicating this matter, the average price of breast reduction is $7,000 alone, with extra care incurring additional cost. The rising annual number of cosmetic and medical surgeries is causation enough to implement intraoperative and perioperative protocols that anticipate and prevent known postoperative complications, Regenative officials say.
It’s something Meglin has seen firsthand. He says one of his patients underwent an elective reduction mammoplasty after losing 35 lbs. post-pregnancy and experienced postoperative wound dehiscence, meaning the wound split open. Despite eight weeks of conservative management, she continued to suffer from a nearly 4 cm open wound. The sensitive region of her wound warranted rapid closure to avoid further pain and infection.
A single dose of a Wharton’s jelly flowable allograft applied around and under the wound bed, in conjunction with hyperbaric oxygen chamber treatments, accelerated wound closure from three months to three weeks. The patient achieved 100% epithelialization and closure of the wound twenty-one days after the initial evaluation with Meglin, he says.
Further, Regenative has been tracking data in a comprehensive repository in which physicians across specialties submit patient data as they track patient outcomes up to 120 days after the patient receives an application of Regenative’s products. There has been minimal literature on the regenerative applications of Wharton’s jelly, an umbilical cord tissue allograft, in soft-tissue structural damage such as in ulcers, pressure sores, and surgical incisions.
Moreover, this data repository has allowed Regenative to publish articles on the benefits of dehydrated amniotic membrane allografts in the closure of diabetic foot ulcers and chronic venous ulcers, advancing medical knowledge within the space.
“This retrospective data repository is designed to promote a value-based, outcomes-focused practice and has inspired case studies and peer-reviewed research,” says Regenative Labs CEO Tyler Barrett. We are calling on all physicians across the country to engage with us and advance the field of regenerative medicine.”
